Physician profile
Brian J Heineman
NPI 1548341035
$5,724.72
in general payments reported to CMS, 2019-2025
38 companies · $685 in 2025
The $685 reported for 2025 was more than what 78% of Adolescent Medicine (Family Medicine) providers received nationally (typical 2025 total: $135).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $683 · 2021: $1,117 · 2022: $1,182 · 2023: $746 · 2024: $467 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.52 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,064.15 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $821.61 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $489.98 | 2019-2025 | |
| Lilly USA, LLC | $423.93 | 2019-2023 | Jardiance, Trulicity, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.62 | 2020-2025 | Jardiance |
| Abbvie INC. | $317.86 | 2021-2024 | |
| Novo Nordisk INC | $253.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $248.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $245.43 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $222.70 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.87 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $93.90 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Harmony Biosciences LLC | $93.13 | 2022-2025 | Wakix |
| Mylan Specialty L.P. | $92.45 | 2021-2022 | |
| Exact Sciences Corporation | $88.11 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Heineman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.